Peter Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, currently serving as Bio-Path’s president, chief executive officer, chief financial officer, and chairman of the Board of Directors. Mr. Nielsen established Bio-Path in 2007 and led the development of the company’s novel antisense oligonucleotide technology. Over the ensuing years, Mr. Nielsen oversaw the preclinical and clinical advancement of Bio-Path’s pipeline of product candidates, including prexigebersen, the company’s public market debut, and the foundation of a strong intellectual property portfolio, including patents for composition of matter and method of use. Prior to co-founding Bio-Path, Mr. Nielsen has worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He earned degrees in engineering, mathematics, and an MBA in finance from the University of California at Berkeley.
Mr. Cleaver has served as chief financial officer of Porto Energy Corp., junior oil and gas exploration company listed on the Canadian Venture Exchange, since February 2011. Prior to his elevation to chief financial officer, Mr. Cleaver served as chief accounting officer. Mr. Cleaver served as corporate controller and then as vice president and chief accounting officer for BPZ Energy from October 2006 to mid-2010. Prior to joining BPZ, Mr. Cleaver was engaged as a consultant for a variety of public companies such as Rosetta Resources, Calpine Natural Gas and Index Oil and Gas. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor of Business Administration - Accounting from Texas A&M University.
Doug Morris is a co-founder of Bio-Path and a co-founding director. Mr. Morris has a number of administrative responsibilities, including working with retail broker/dealers in raising capital for small cap companies, and interfacing with existing shareholders. Mr. Morris has a Bachelor of Arts from Brigham Young University and is working towards a Master of Public Administration from the University of Southern California.
Mr. Colonnese brings over 30 years of broad executive management skills and financial experience at Fortune 500 as well as small entrepreneurial companies. He currently serves as the executive vice president and chief financial officer of Aviragen Therapeutics, Inc., a NASDAQ-listed antiviral drug development company. Earlier in his career, Mr. Colonnese was chief financial officer at a number of biotechnology companies including Stealth BioTherapeutics, Transgenomic Inc., and AtheroGenics Inc. Mr. Colonnese also served as vice president of financial operations at Schering-Plough Corporation, now part of Merck, one of the world’s largest pharmaceutical companies. In these roles, he was responsible for raising $870 million in equity and debt capital, as well as $100 million from partnerships, and directing two companies through their initial public offerings. Mr. Colonnese holds a Master of Business Administration from Fairleigh Dickinson University and a Bachelor of Science, magna cum laude from Ithaca College.
Paul Aubert currently serves individuals and corporations through his private law practice. In addition, he serves as general counsel to four companies, including a developer of dental implant. Prior to launching his own practice, he served as general counsel of Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX), a specialty pharmaceutical company. For the 13 years prior to joining Pernix, Mr. Aubert worked in the Corporate and Securities divisions of several law firms, including Weil, Gotshal & Manges and Andrews Kurth LLP, and Winstead PC, where he provided legal advice on general corporate matters as well as securities and M&A transactions to public and private companies. He received his Juris Doctor and MBA from Tulane University in New Orleans, Louisiana in 1996, and his Bachelor of Arts in history from Louisiana State University - Baton Rouge in 1990.